Wall Street brokerages predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report sales of $40.90 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Enanta Pharmaceuticals’ earnings. The highest sales estimate is $42.44 million and the lowest is $38.81 million. Enanta Pharmaceuticals posted sales of $44.05 million during the same quarter last year, which would indicate a negative year over year growth rate of 7.2%. The company is scheduled to report its next earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $216.24 million for the current fiscal year, with estimates ranging from $210.26 million to $227.39 million. For the next financial year, analysts anticipate that the firm will post sales of $195.42 million, with estimates ranging from $179.24 million to $213.99 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Enanta Pharmaceuticals.
Get Enanta Pharmaceuticals alerts:Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.21). The firm had revenue of $69.89 million for the quarter, compared to analysts’ expectations of $71.27 million. Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The company’s revenue for the quarter was up 83.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 EPS.
ENTA has been the topic of a number of analyst reports. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 8th. ValuEngine downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 8th. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 27th. Finally, TheStreet downgraded shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $100.00.
ENTA opened at $95.95 on Thursday. The company has a market cap of $1.76 billion, a PE ratio of 27.57 and a beta of 1.27. Enanta Pharmaceuticals has a 52-week low of $64.08 and a 52-week high of $127.77.
In other Enanta Pharmaceuticals news, VP Yat Sun Or sold 27,684 shares of Enanta Pharmaceuticals stock in a transaction on Monday, February 11th. The shares were sold at an average price of $89.39, for a total value of $2,474,672.76. Following the completion of the transaction, the vice president now owns 320,169 shares of the company’s stock, valued at $28,619,906.91. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce L. A. Carter sold 7,734 shares of Enanta Pharmaceuticals stock in a transaction on Tuesday, February 12th. The stock was sold at an average price of $90.01, for a total transaction of $696,137.34. Following the completion of the transaction, the director now directly owns 2,734 shares of the company’s stock, valued at approximately $246,087.34. The disclosure for this sale can be found here. Insiders have sold 38,688 shares of company stock valued at $3,482,376 in the last three months. Corporate insiders own 11.35% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in ENTA. PNC Financial Services Group Inc. boosted its holdings in Enanta Pharmaceuticals by 64.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 249 shares during the period. Bank of Montreal Can boosted its holdings in Enanta Pharmaceuticals by 33.0% in the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares during the period. Smith Asset Management Group LP acquired a new position in Enanta Pharmaceuticals in the third quarter worth $173,000. People s United Financial Inc. acquired a new position in Enanta Pharmaceuticals in the third quarter worth $212,000. Finally, Pacer Advisors Inc. acquired a new position in Enanta Pharmaceuticals in the third quarter worth $230,000. 87.23% of the stock is owned by hedge funds and other institutional investors.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
See Also: Different Types of Derivatives
Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment